Compare Biocon Ltd with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs DISHMAN PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON DISHMAN PHARMA BIOCON /
DISHMAN PHARMA
 
P/E (TTM) x 26.6 25.1 106.2% View Chart
P/BV x 3.0 3.3 90.0% View Chart
Dividend Yield % 0.3 0.7 49.2%  

Financials

 BIOCON    DISHMAN PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
DISHMAN PHARMA
Mar-16
BIOCON /
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs707374 188.9%   
Low Rs554129 429.6%   
Sales per share (Unadj.) Rs91.9197.8 46.5%  
Earnings per share (Unadj.) Rs16.721.2 78.8%  
Cash flow per share (Unadj.) Rs24.234.7 69.6%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.8 20.0%  
Book value per share (Unadj.) Rs101.6179.9 56.5%  
Shares outstanding (eoy) m600.0080.69 743.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.91.3 539.3%   
Avg P/E ratio x37.711.9 318.0%  
P/CF ratio (eoy) x26.17.2 359.9%  
Price / Book Value ratio x6.21.4 443.5%  
Dividend payout %6.09.4 63.5%   
Avg Mkt Cap Rs m378,33020,306 1,863.2%   
No. of employees `0006.10.8 739.6%   
Total wages/salary Rs m11,6535,355 217.6%   
Avg. sales/employee Rs Th8,994.319,252.7 46.7%   
Avg. wages/employee Rs Th1,900.76,459.5 29.4%   
Avg. net profit/employee Rs Th1,635.32,064.1 79.2%   
INCOME DATA
Net Sales Rs m55,14415,961 345.5%  
Other income Rs m1,444265 544.1%   
Total revenues Rs m56,58816,226 348.8%   
Gross profit Rs m15,8834,103 387.1%  
Depreciation Rs m4,4781,091 410.6%   
Interest Rs m709944 75.1%   
Profit before tax Rs m12,1402,334 520.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123624 340.4%   
Profit after tax Rs m10,0261,711 585.9%  
Gross profit margin %28.825.7 112.0%  
Effective tax rate %17.526.7 65.4%   
Net profit margin %18.210.7 169.6%  
BALANCE SHEET DATA
Current assets Rs m48,22811,018 437.7%   
Current liabilities Rs m30,3769,517 319.2%   
Net working cap to sales %32.49.4 344.3%  
Current ratio x1.61.2 137.1%  
Inventory Days Days68110 61.8%  
Debtors Days Days8635 245.4%  
Net fixed assets Rs m64,13016,304 393.3%   
Share capital Rs m3,000161 1,858.7%   
"Free" reserves Rs m57,98012,907 449.2%   
Net worth Rs m60,98014,516 420.1%   
Long term debt Rs m15,7664,189 376.3%   
Total assets Rs m121,92429,805 409.1%  
Interest coverage x18.13.5 522.1%   
Debt to equity ratio x0.30.3 89.6%  
Sales to assets ratio x0.50.5 84.5%   
Return on assets %8.88.9 98.8%  
Return on equity %16.411.8 139.5%  
Return on capital %16.817.5 95.6%  
Exports to sales %28.124.8 113.4%   
Imports to sales %18.93.7 504.7%   
Exports (fob) Rs m15,5063,956 391.9%   
Imports (cif) Rs m10,399596 1,743.9%   
Fx inflow Rs m15,5064,952 313.2%   
Fx outflow Rs m10,399697 1,492.4%   
Net fx Rs m5,1074,255 120.0%   
CASH FLOW
From Operations Rs m11,5462,786 414.4%  
From Investments Rs m-7,138-1,529 466.9%  
From Financial Activity Rs m-2,417-941 256.8%  
Net Cashflow Rs m2,103316 664.7%  

Share Holding

Indian Promoters % 40.4 61.4 65.8%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 3.7 227.0%  
FIIs % 10.7 12.7 84.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 22.1 90.0%  
Shareholders   109,995 46,261 237.8%  
Pledged promoter(s) holding % 0.0 35.8 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 428 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended their trading session on a positive note today.

Related Views on News

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

How to Become a One Stock Crorepati(Profit Hunter)

Feb 6, 2020

A little known Indian stock that is set to turn around its own fortunes, and your wealth, if you just have the foresight to get in on time...

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

How to Use Stop Losses in Your Trading(Fast Profits Daily)

Feb 13, 2020

There's more to stop losses than just limiting a trading loss. Find out more...

No Change in My Long-Term View on the Rebirth of India Stocks(The 5 Minute Wrapup)

Feb 6, 2020

Why the recent post budget volatility has not affected my bullish view on the Rebirth of India stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Feb 19, 2020 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS